Stonehage Fleming Financial Services’s Psyence Biomedical PBM Stock Holding History

Stonehage Fleming Financial Services’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$218	Sell	89 -1	-1%	-$3	﹤0.01%	224
2025 Q4	$422	Hold	90	–	–	﹤0.01%	219
2025 Q3	$1.79K	Hold	90	–	–	﹤0.01%	214
2025 Q2	$2.99K	Hold	90	–	–	﹤0.01%	205
2025 Q1	$2.69K	Buy	+90	New	+$5.73K	﹤0.01%	183
2024 Q4	–	Sell	-22	Closed	-$8.05K	–	240
2024 Q3	$8.05K	Buy	+22	New	+$29.8K	﹤0.01%	205

Other funds holding PBM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Stonehage Fleming Financial Services's PBM Position: Q1 2026 in Review

Stonehage Fleming Financial Services reduced its Psyence Biomedical (PBM) stake by 1.1% in Q1 2026, selling an estimated $3 and leaving 89 shares worth $218. The position accounts for ﹤0.01% of the portfolio, ranked #224.

Stonehage Fleming Financial Services first reported a position in PBM in Q3 2024 and has held it in 6 quarters since. The position peaked at $8.05K in Q3 2024. 2 funds tracked by Wall St. Rank hold PBM as of Q1 2026.

Stonehage Fleming Financial Services held 89 shares of Psyence Biomedical worth $218 as of Q1 2026.
Stonehage Fleming Financial Services sold 1 Psyence Biomedical share in Q1 2026, an estimated $3.
Psyence Biomedical made up ﹤0.01% of Stonehage Fleming Financial Services's portfolio in Q1 2026, its #224 holding.
Stonehage Fleming Financial Services first reported a position in Psyence Biomedical in Q3 2024 and has held it in 6 quarters since.
Stonehage Fleming Financial Services's Psyence Biomedical position peaked at $8.05K in Q3 2024.
2 funds tracked by Wall St. Rank held Psyence Biomedical as of Q1 2026.

Based on Stonehage Fleming Financial Services's 13F filing for Q1 2026, filed 13 May 2026.